Yasuhiro Matsumura

List of Publications by Year
in descending order

119 papers	6,103 citations	76322 40 h-index	71682 76 g-index
127 all docs	127 docs citations	127 times ranked	6995 citing authors

#	Article	IF	Citations
1	A Novel and Potent Thrombolytic Fusion Protein Consisting of Anti-Insoluble Fibrin Antibody and Mutated Urokinase. Thrombosis and Haemostasis, 2022, 122, 057-066.	3.4	3
2	The natural sulfoglycolipid derivative SQAP improves the therapeutic efficacy of tissue factor-targeted radioimmunotherapy in the stroma-rich pancreatic cancer model BxPC-3. Translational Oncology, 2022, 15, 101285.	3.7	1
3	35 years of discussions with Prof. Maeda on the EPR effect and future directions. Journal of Controlled Release, 2022, 348, 966-969.	9.9	9
4	High expression of TMEM180, a novel tumour marker, is associated with poor survival in stage III colorectal cancer. BMC Cancer, 2021, 21, 302.	2.6	11
5	Radioimmunotherapy with an 211 At–labeled anti–tissue factor antibody protected by sodium ascorbate. Cancer Science, 2021, 112, 1975-1986.	3.9	12
6	Barriers to antibody therapy in solid tumors, and their solutions. Cancer Science, 2021, 112, 2939-2947.	3.9	13
7	TMEM180 contributes to SW480 human colorectal cancer cell proliferation through intra-cellular metabolic pathways. Translational Oncology, 2021, 14, 101186.	3.7	1
8	Cancer stromal targeting therapy to overcome the pitfall of EPR effect. Advanced Drug Delivery Reviews, 2020, 154-155, 142-150.	13.7	28
9	Reinforcement of antitumor effect of micelles containing anticancer drugs by binding of an anti-tissue factor antibody without direct cytocidal effects. Journal of Controlled Release, 2020, 323, 138-150.	9.9	14
10	Development of tissue factor-targeted liposomes for effective drug delivery to stroma-rich tumors. Journal of Controlled Release, 2020, 323, 519-529.	9.9	10
11	Platelet protein S limits venous but not arterial thrombosis propensity by controlling coagulation in the thrombus. Blood, 2020, 135, 1969-1982.	1.4	17
12	Contribution from Synthetic Organic Chemistry and Glycoscience to ADC Development: Homogeneous ADC Preparation and Development of Cancer Stromal Targeting Therapy. Yuki Gosei Kagaku Kyokaishi/Journal of Synthetic Organic Chemistry, 2020, 78, 485-494.	0.1	0
13	Thinking about The Japan Society of DDS. Drug Delivery System, 2020, 35, 3-3.	0.0	0
14	Selection of Tumor models. Drug Delivery System, 2020, 35, 443-447.	0.0	0
15	Serum level of octanoic acid predicts the efficacy of chemotherapy for colorectal cancer. Oncology Letters, 2019, 17, 831-842.	1.8	10
16	Topological analysis of TMEM180, a newly identified membrane protein that is highly expressed in colorectal cancer cells. Biochemical and Biophysical Research Communications, 2019, 520, 566-572.	2.1	12
17	Evaluation of the antitumor mechanism of antibody–drug conjugates against tissue factor in stroma–rich allograft models. Cancer Science, 2019, 110, 3296-3305.	3.9	11
18	Anti–tissue factor antibody–mediated immuno–SPECT imaging of tissue factor expression in mouse models of pancreatic cancer. Oncology Reports, 2019, 41, 2371-2378.	2.6	8

#	Article	IF	Citations
19	Characterization of Antibody Products Obtained through Enzymatic and Nonenzymatic Glycosylation Reactions with a Glycan Oxazoline and Preparation of a Homogeneous Antibody–Drug Conjugate via Fc *N*-Glycan. Bioconjugate Chemistry, 2019, 30, 1343-1355.	3.6	30
20	ET-05 PRECLINICAL STUDY OF AN ANTI-HUMAN TISSUE FACTOR ANTIBODY-DRUG CONJUGATE IN A MALIGNANT GLIOMA XENOGRAFT MODEL. Neuro-Oncology Advances, 2019, 1, ii9-ii9.	0.7	0
21	Preclinical Studies of ADC Therapy for Solid Tumors. , 2019, , 125-154.		0
22	Significant antitumor effect of an antibody against TMEM180, a new colorectal cancer–specific molecule. Cancer Science, 2019, 110, 761-770.	3.9	20
23	Principle of CAST Strategy. , 2019, , 255-267.		2
24	Cancer and Blood Coagulation. , 2019, , 23-40.		2
25	Preclinical studies of immunomicelles incorporating anticancer drugs. Drug Delivery System, 2019, 34, 29-37.	0.0	0
26	CAST Therapy. , 2019, , 269-288.		0
27	The Current Status of Cancer Drug Delivery Systems and Future Directions. , 2019, , 311-319.		0
28	Targeting anticoagulant protein S to improve hemostasis in hemophilia. Blood, 2018, 131, 1360-1371.	1.4	57
29	Near-infrared photoimmunotherapy of pancreatic cancer using an indocyanine green-labeled anti-tissue factor antibody. World Journal of Gastroenterology, 2018, 24, 5491-5504.	3.3	26
30	A phase II study of NK012, a polymeric micelle formulation of SN-38, in unresectable, metastatic or recurrent colorectal cancer patients. Cancer Chemotherapy and Pharmacology, 2018, 82, 1021-1029.	2.3	32
31	Chemotherapy payload of anti-insoluble fibrin antibody-drug conjugate is released specifically upon binding to fibrin. Scientific Reports, 2018, 8, 14211.	3.3	31
32	Tuned Density of Anti-Tissue Factor Antibody Fragment onto siRNA-Loaded Polyion Complex Micelles for Optimizing Targetability into Pancreatic Cancer Cells. Biomacromolecules, 2018, 19, 2320-2329.	5.4	34
33	Collagen type I induces EGFR–TKI resistance in EGFR–mutated cancer cells by mTOR activation through Akt–independent pathway. Cancer Science, 2018, 109, 2063-2073.	3.9	39
34	Influence of the dissociation rate constant on the intra-tumor distribution of antibody-drug conjugate against tissue factor. Journal of Controlled Release, 2018, 284, 49-56.	9.9	48
35	Development of CAST therapy based on the EPR effect: lesson from clinical trials.. Drug Delivery System, 2018, 33, 139-149.	0.0	2
36	Mass spectrometry imaging for early discovery and development of cancer drugs. AIMS Medical Science, 2018, 5, 162-180.	0.4	2

#	Article	IF	Citations
37	Molecular imaging using an anti-human tissue factor monoclonal antibody in an orthotopic glioma xenograft model. Scientific Reports, 2017, 7, 12341.	3.3	20
38	Immunoregulation by IL-7R-targeting antibody-drug conjugates: overcoming steroid-resistance in cancer and autoimmune disease. Scientific Reports, 2017, 7, 10735.	3.3	28
39	Development of Antibody–Drug Conjugates Using DDS and Molecular Imaging. Bioengineering, 2017, 4, 78.	3.5	23
40	Preclinical efficacy of Sym004, novel anti-EGFR antibody mixture, in esophageal squamous cell carcinoma cell lines. Oncotarget, 2017, 8, 11020-11029.	1.8	9
41	High expression of miR-181c as a predictive marker of recurrence in stage II colorectal cancer. Oncotarget, 2017, 8, 6970-6983.	1.8	36
42	Imaging mass spectrometry for the precise design of antibody-drug conjugates. Scientific Reports, 2016, 6, 24954.	3.3	33
43	Tumour imaging by the detection of fibrin clots in tumour stroma using an anti-fibrin Fab fragment. Scientific Reports, 2016, 6, 23613.	3.3	33
44	Utility of epirubicin–incorporating micelles tagged with anti–tissue factor antibody clone with no anticoagulant effect. Cancer Science, 2016, 107, 335-340.	3.9	18
45	Development of polymeric micelles for targeting intractable cancers. Cancer Science, 2016, 107, 867-874.	3.9	149
46	Effect of combined treatment with micelle-incorporated cisplatin (NC-6004) and S-1 on human gastric cancer xenografts. Molecular and Clinical Oncology, 2016, 5, 817-822.	1.0	4
47	Phase I study of NK105, a nanomicellar paclitaxel formulation, administered on a weekly schedule in patients with solid tumors. Investigational New Drugs, 2016, 34, 750-759.	2.6	28
48	Construction of possible integrated predictive index based on EGFR and ANXA3 polymorphisms for chemotherapy response in fluoropyrimidine-treated Japanese gastric cancer patients using a bioinformatic method. BMC Cancer, 2015, 15, 718.	2.6	11
49	Antitumor effect of antitissue factor antibody–MMAE conjugate in human pancreatic tumor xenografts. International Journal of Cancer, 2015, 137, 1457-1466.	5.1	62
50	Enhanced antitumor effect of anti–tissue factor antibody–conjugated epirubicin–incorporating micelles in xenograft models. Cancer Science, 2015, 106, 627-634.	3.9	35
51	Feasibility study of the Fab fragment of a monoclonal antibody against tissue factor as a diagnostic tool. International Journal of Oncology, 2015, 47, 2107-2114.	3.3	17
52	General considerations regarding the in vitro and in vivo properties of block copolymer micelle products and their evaluation. Journal of Controlled Release, 2015, 210, 76-83.	9.9	63
53	Antibody fragment-conjugated polymeric micelles incorporating platinum drugs for targeted therapy of pancreatic cancer. Biomaterials, 2015, 39, 23-30.	11.4	125
54	Application of a Combination of a Knowledge-Based Algorithm and 2-Stage Screening to Hypothesis-Free Genomic Data on Irinotecan-Treated Patients for Identification of a Candidate Single Nucleotide Polymorphism Related to an Adverse Effect. PLoS ONE, 2014, 9, e105160.	2.5	5

#	Article	IF	Citations
55	The initiatives for regulatory science researches of nanomedicines. Drug Delivery System, 2014, 29, 217-225.	0.0	2
56	Marked antitumor effect of NK012, a SN-38-incorporating micelle formulation, in a newly developed mouse model of liver metastasis resulting from gastric cancer. Therapeutic Delivery, 2014, 5, 129-138.	2.2	8
57	Effect of combined treatment with the epirubicinâ€incorporating micelles (NCâ€6300) and 1,2â€diaminocyclohexane platinum (II)â€incorporating micelles (NCâ€4016) on a human gastric cancer model. International Journal of Cancer, 2014, 135, 214-223.	5.1	35
58	New molecular diagnosis and screening methods for colorectal cancer using fecal protein, DNA and RNA. Expert Review of Molecular Diagnostics, 2014, 14, 107-120.	3.1	7
59	Preparation and characterization of antiâ€tissue factor singleâ€chain variable fragment antibody for cancer diagnosis. Cancer Science, 2014, 105, 1631-1637.	3.9	10
60	The Drug Discovery by NanoMedicine and its Clinical Experience. Japanese Journal of Clinical Oncology, 2014, 44, 515-525.	1.3	75
61	Role of SLC6A6 in promoting the survival and multidrug resistance of colorectal cancer. Scientific Reports, 2014, 4, 4852.	3.3	35
62	A clinical trial can determine the course of DDS development. Drug Delivery System, 2014, 29, 39-50.	0.0	1
63	Identification of a candidate single-nucleotide polymorphism related to chemotherapeutic response through a combination of knowledge-based algorithm and hypothesis-free genomic data. Journal of Bioscience and Bioengineering, 2013, 116, 768-773.	2.2	8
64	Fecal miR-106a Is a Useful Marker for Colorectal Cancer Patients with False-Negative Results in Immunochemical Fecal Occult Blood Test. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 1844-1852.	2.5	73
65	Discovery of an uncovered region in fibrin clots and its clinical significance. Scientific Reports, 2013, 3, 2604.	3.3	44
66	Development of a diketopiperazine-forming dipeptidyl Gly-Pro spacer for preparation of an antibodyâ€"drug conjugate. MedChemComm, 2013, 4, 792.	3.4	19
67	Application of the Fecal MicroRNA Test to the Residuum from the Fecal Occult Blood Test. Japanese Journal of Clinical Oncology, 2013, 43, 726-733.	1.3	17
68	<scp>NC</scp>â€6300, an epirubicinâ€incorporating micelle, extends the antitumor effect and reduces the cardiotoxicity of epirubicin. Cancer Science, 2013, 104, 920-925.	3.9	114
69	Tailored immunoconjugate therapy depending on a quantity of tumor stroma. Cancer Science, 2013, 104, 231-237.	3.9	28
70	The significance of microscopic mass spectrometry with high resolution in the visualisation of drug distribution. Scientific Reports, 2013, 3, 3050.	3.3	39
71	Tumor stromal barrier and cancer stromal targeting therapy. Microvascular Reviews and Communications, 2013, 6, 2-8.	0.0	3
72	Clinical development of anticancer agents incorporating micelles in oncological treatment. Drug Delivery System, 2013, 28, 215-220.	0.0	1

#	Article	IF	Citations
73	Cancer Stromal Targeting (CAST) Therapy and Tailored Antibody Drug Conjugate Therapy Depending on the Nature of Tumor Stroma. , 2013, , 161-181.		0
74	Cancer Stromal Targeting. Drug Delivery System, 2013, 28, 396-405.	0.0	0
75	Application of miRNA expression analysis on exfoliated colonocytes for diagnosis of colorectal cancer. Gastrointestinal Cancer: Targets and Therapy, 2012, , 11.	5.5	1
76	Phase II study of NK105, a paclitaxel-incorporating micellar nanoparticle, for previously treated advanced or recurrent gastric cancer. Investigational New Drugs, 2012, 30, 1621-1627.	2.6	213
77	Cancer stromal targeting (CAST) therapy. Advanced Drug Delivery Reviews, 2012, 64, 710-719.	13.7	99
78	Cancer-Stroma Targeting Therapy by Cytotoxic Immunoconjugate Bound to the Collagen 4 Network in the Tumor Tissue. Bioconjugate Chemistry, 2011, 22, 1776-1783.	3.6	70
79	The inhibition of pancreatic cancer invasion-metastasis cascade in both cellular signal and blood coagulation cascade of tissue factor by its neutralisation antibody. European Journal of Cancer, 2011, 47, 2230-2239.	2.8	41
80	Clinical development of nano-DDS. Drug Delivery System, 2011, 26, 20-28.	0.0	0
81	Novel virtual cytological analysis for the detection of endometrial cancer cells using autoscan fluoromicroscopy. Cancer Science, 2011, 102, 1068-1075.	3.9	3
82	New concept of cytotoxic immunoconjugate therapy targeting cancerâ€induced fibrin clots. Cancer Science, 2011, 102, 1396-1402.	3.9	69
83	EPR effect based drug design and clinical outlook for enhanced cancer chemotherapy. Advanced Drug Delivery Reviews, 2011, 63, 129-130.	13.7	193
84	Preclinical and clinical studies of NK012, an SN-38-incorporating polymeric micelles, which is designed based on EPR effect. Advanced Drug Delivery Reviews, 2011, 63, 184-192.	13.7	205
85	Exosome can prevent RNase from degrading microRNA in feces. Journal of Gastrointestinal Oncology, 2011, 2, 215-22.	1.4	145
86	Additive effects of drug transporter genetic polymorphisms on irinotecan pharmacokinetics/pharmacodynamics in Japanese cancer patients. Cancer Chemotherapy and Pharmacology, 2010, 66, 95-105.	2.3	55
87	The antitumor activity of NK012, an SNâ€38â€"incorporating micelle, in combination with bevacizumab against lung cancer xenografts. Cancer, 2010, 116, 4597-4604.	4.1	22
88	Synergistic antitumor activity of the SNâ€38â€incorporating polymeric micelles NK012 with Sâ€1 in a mouse model of nonâ€small cell lung cancer. International Journal of Cancer, 2010, 127, 2699-2706.	5.1	21
89	Detailed Distribution of NK012, an SN-38â€"Incorporating Micelle, in the Liver and Its Potent Antitumor Effects in Mice Bearing Liver Metastases. Clinical Cancer Research, 2010, 16, 4822-4831.	7.0	24
90	MicroRNA Expression Profiling of Exfoliated Colonocytes Isolated from Feces for Colorectal Cancer Screening. Cancer Prevention Research, 2010, 3, 1435-1442.	1.5	197

#	Article	IF	Citations
91	Phase I Study of NK012, a Novel SN-38–Incorporating Micellar Nanoparticle, in Adult Patients with Solid Tumors. Clinical Cancer Research, 2010, 16, 5058-5066.	7.0	136
92	Antitumor Effect of NK012, a 7-Ethyl-10-Hydroxycamptothecin–Incorporating Polymeric Micelle, on U87MG Orthotopic Glioblastoma in Mice Compared with Irinotecan Hydrochloride in Combination with Bevacizumab. Clinical Cancer Research, 2010, 16, 521-529.	7.0	35
93	Antitumour activity of NK012, SN-38-incorporating polymeric micelles, in hypovascular orthotopic pancreatic tumour. European Journal of Cancer, 2010, 46, 650-658.	2.8	26
94	Cancer Chemotherapy by DDS. Oleoscience, 2010, 10, 25-30.	0.0	0
95	Antitumor Activity of NK012 Combined with Cisplatin against Small Cell Lung Cancer and Intestinal Mucosal Changes in Tumor-Bearing Mouse after Treatment. Clinical Cancer Research, 2009, 15, 4348-4355.	7.0	38
96	Potent antitumor effect of SN–38–incorporating polymeric micelle, NK012, against malignant glioma. International Journal of Cancer, 2009, 124, 2505-2511.	5.1	62
97	Preclinical and clinical studies of anticancer agent–incorporating polymer micelles. Cancer Science, 2009, 100, 572-579.	3.9	474
98	Synergistic antitumor activity of the novel SN–38–incorporating polymeric micelles, NK012, combined with 5–fluorouracil in a mouse model of colorectal cancer, as compared with that of irinotecan plus 5–fluorouracil. International Journal of Cancer, 2008, 122, 2148-2153.	5.1	53
99	Poly (amino acid) micelle nanocarriers in preclinical and clinical studies. Advanced Drug Delivery Reviews, 2008, 60, 899-914.	13.7	253
100	Enhanced distribution of NK012, a polymeric micelle–encapsulated SN–38, and sustained release of SN–38 within tumors can beat a hypovascular tumor. Cancer Science, 2008, 99, 1258-1264.	3.9	42
101	Detection of colorectal cancer cells from feces using quantitative real–time RT–PCR for colorectal cancer diagnosis. Cancer Science, 2008, 99, 1977-1983.	3.9	34
102	Polymeric Micellar Delivery Systems in Oncology. Japanese Journal of Clinical Oncology, 2008, 38, 793-802.	1.3	114
103	Antitumor Effect of SN-38–Releasing Polymeric Micelles, NK012, on Spontaneous Peritoneal Metastases from Orthotopic Gastric Cancer in Mice Compared with Irinotecan. Cancer Research, 2008, 68, 9318-9322.	0.9	43
104	Novel SN-38–Incorporated Polymeric Micelle, NK012, Strongly Suppresses Renal Cancer Progression. Cancer Research, 2008, 68, 1631-1635.	0.9	61
105	New method for colorectal cancer diagnosis based on SSCP analysis of DNA from exfoliated colonocytes in naturally evacuated feces. Anticancer Research, 2008, 28, 145-50.	1.1	9
106	Genetic variations and haplotype structures of the DPYD gene encoding dihydropyrimidine dehydrogenase in Japanese and their ethnic differences. Journal of Human Genetics, 2007, 52, 804-819.	2.3	51
107	Novel SN-38–Incorporating Polymeric Micelles, NK012, Eradicate Vascular Endothelial Growth Factor–Secreting Bulky Tumors. Cancer Research, 2006, 66, 10048-10056.	0.9	234
108	A New Method for Isolating Colonocytes From Naturally Evacuated Feces and Its Clinical Application to Colorectal Cancer Diagnosis. Gastroenterology, 2005, 129, 1918-1927.	1.3	55

#	Article	IF	Citations
109	Antitumor effect of MCC-465, pegylated liposomal doxorubicin tagged with newly developed monoclonal antibody GAH, in colorectal cancer xenografts. Cancer Science, 2004, 95, 608-613.	3.9	74
110	Novel cisplatin-incorporated polymeric micelles can eradicate solid tumors in mice. Cancer Research, 2003, 63, 8977-83.	0.9	486
111	Pharmaceutical and Biomedical Differences between Micellar Doxorubicin (NK911) and Liposomal Doxorubicin (Doxil). Japanese Journal of Cancer Research, 2002, 93, 1145-1153.	1.7	100
112	Incorporation of the Anticancer Agent KRN5500 into Polymeric Micelles Diminishes the Pulmonary Toxicity. Japanese Journal of Cancer Research, 2002, 93, 1237-1243.	1.7	28
113	Cisplatin-incorporated Polymeric Micelles Eliminate Nephrotoxicity, While Maintaining Antitumor Activity. Japanese Journal of Cancer Research, 2001, 92, 328-336.	1.7	86
114	Reduction of the Side Effects of an Antitumor Agent, KRN5500, by Incorporation of the Drug into Polymeric Micelles. Japanese Journal of Cancer Research, 1999, 90, 122-128.	1.7	49
115	Incorporation of water-insoluble anticancer drug into polymeric micelles and control of their particle size. Journal of Controlled Release, 1998, 55, 219-229.	9.9	186
116	Abnormal expression of CD44 variants in the exfoliated cells in the feces of patients with colorectal cancer. Gastroenterology, 1998, 114, 1196-1205.	1.3	59
117	Kinin-generating Cascade in Advanced Cancer Patients and in vitro Study. Japanese Journal of Cancer Research, 1991, 82, 732-741.	1.7	99
118	Involvement of the Kinin-generating Cascade in Enhanced Vascular Permeability in Tumor Tissue. Japanese Journal of Cancer Research, 1988, 79, 1327-1334.	1.7	150
119	Trends of food consumption pattern reflected upon economic growth. [Minzoku Eisei] Race Hygiene, 1981, 47, 138-147.	0.0	0